Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

gilead sciences inc. - GILD

GILD

Close Chg Chg %
137.34 0.77 0.56%

Closed Market

138.11

+0.77 (0.56%)

Volume: 6.73M

Last Updated:

Mar 24, 2026, 4:00 PM EDT

Trade Now

Company Overview: gilead sciences inc. - GILD

GILD Key Data

Open

$136.80

 Day Range

136.47 - 138.37

52 Week Range

93.37 - 157.27

 Market Cap

$170.50B

Shares Outstanding

1.24B

 Public Float

1.24B

Beta

0.38

 Rev. Per Employee

N/A

P/E Ratio

20.25

 EPS

$6.84

Yield

230.09%

 Dividend

$0.82

EX-DIVIDEND DATE

Mar 13, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

6.83M

  

GILD Performance

1 Week
 
 0.09%
 
1 Month
 
 -7.79%
 
3 Months
 
 10.14%
 
1 Year
 
 28.26%
 
5 Years
 
 110.52%
 

GILD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 32
Full Ratings ➔

About gilead sciences inc. - GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

GILD At a Glance

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, California 94404
Phone 1-650-574-3000 Revenue 29.45B
Industry Biotechnology Net Income 8.51B
Sector Health Technology 2025 Sales Growth 2.51%
Fiscal Year-end 12 / 2026 Employees 17,000
View SEC Filings

GILD Valuation

P/E Current 20.235
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 18.101
Price to Sales Ratio 5.231
Price to Book Ratio 6.709
Price to Cash Flow Ratio 15.37
Enterprise Value to EBITDA 11.65
Enterprise Value to Sales 5.769
Total Debt to Enterprise Value 0.15

GILD Efficiency

Revenue/Employee 1,732,235.294
Income Per Employee 500,588.235
Receivables Turnover 5.994
Total Asset Turnover 0.499

GILD Liquidity

Current Ratio 1.553
Quick Ratio 1.403
Cash Ratio 0.814

GILD Profitability

Gross Margin 78.844
Operating Margin 40.145
Pretax Margin 33.265
Net Margin 28.898
Return on Assets 14.422
Return on Equity 40.492
Return on Total Capital 17.639
Return on Invested Capital 18.899

GILD Capital Structure

Total Debt to Total Equity 112.501
Total Debt to Total Capital 52.941
Total Debt to Total Assets 43.273
Long-Term Debt to Equity 99.687
Long-Term Debt to Total Capital 46.912
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Gilead Sciences Inc. - GILD

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
27.09B 27.06B 28.73B 29.45B
Sales Growth
-1.05% -0.10% +6.17% +2.51%
Cost of Goods Sold (COGS) incl D&A
5.66B 6.02B 6.25B 6.23B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.10B 2.69B 2.77B 2.76B
Depreciation
323.00M 354.00M 381.00M 370.00M
Amortization of Intangibles
1.78B 2.34B 2.39B 2.39B
COGS Growth
-14.30% +6.40% +3.85% -0.34%
Gross Income
21.43B 21.04B 22.48B 23.22B
Gross Income Growth
+3.16% -1.82% +6.83% +3.30%
Gross Profit Margin
+79.11% +77.76% +78.24% +78.84%
2022 2023 2024 2025 5-year trend
SG&A Expense
10.67B 11.29B 11.82B 11.40B
Research & Development
5.00B 5.76B 5.82B 5.69B
Other SG&A
5.67B 5.54B 6.00B 5.71B
SGA Growth
+0.96% +5.85% +4.61% -3.55%
Other Operating Expense
- - - -
-
Unusual Expense
4.21B 2.31B 9.26B 1.41B
EBIT after Unusual Expense
6.54B 7.44B 1.40B 10.41B
Non Operating Income/Expense
205.00M 366.00M 271.00M 409.00M
Non-Operating Interest Income
- 376.00M 281.00M 349.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
935.00M 944.00M 977.00M 1.02B
Interest Expense Growth
-6.59% +0.96% +3.50% +4.81%
Gross Interest Expense
935.00M 944.00M 977.00M 1.02B
Interest Capitalized
- - - -
-
Pretax Income
5.81B 6.86B 690.00M 9.80B
Pretax Income Growth
-29.77% +17.97% -89.94% +1,319.71%
Pretax Margin
+21.47% +25.35% +2.40% +33.27%
Income Tax
1.25B 1.25B 210.00M 1.29B
Income Tax - Current - Domestic
2.57B 1.86B 1.53B 871.00M
Income Tax - Current - Foreign
232.00M 381.00M 519.00M 256.00M
Income Tax - Deferred - Domestic
(1.66B) (956.00M) (1.95B) 234.00M
Income Tax - Deferred - Foreign
101.00M (40.00M) 105.00M (75.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
4.57B 5.61B 480.00M 8.51B
Minority Interest Expense
- - (26.00M) (52.00M)
-
Net Income
4.59B 5.67B 480.00M 8.51B
Net Income Growth
-26.23% +23.37% -91.53% +1,672.92%
Net Margin Growth
+16.95% +20.94% +1.67% +28.90%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
4.59B 5.67B 480.00M 8.51B
Preferred Dividends
- - - -
-
Net Income Available to Common
4.59B 5.67B 480.00M 8.51B
EPS (Basic)
3.659 4.5393 0.3849 6.8408
EPS (Basic) Growth
-26.17% +24.06% -91.52% +1,677.29%
Basic Shares Outstanding
1.25B 1.25B 1.25B 1.24B
EPS (Diluted)
3.6387 4.5032 0.3825 6.7809
EPS (Diluted) Growth
-26.23% +23.76% -91.51% +1,672.78%
Diluted Shares Outstanding
1.26B 1.26B 1.25B 1.25B
EBITDA
12.86B 12.44B 13.43B 14.58B
EBITDA Growth
+4.97% -3.29% +7.96% +8.60%
EBITDA Margin
+47.48% +45.96% +46.74% +49.52%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 158.923
Number of Ratings 32 Current Quarters Estimate 1.897
FY Report Date 03 / 2026 Current Year's Estimate 8.679
Last Quarter’s Earnings 1.86 Median PE on CY Estimate N/A
Year Ago Earnings 8.15 Next Fiscal Year Estimate 9.665
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 23 21 27 26
Mean Estimate 1.90 2.10 8.68 9.66
High Estimates 2.07 2.49 8.91 10.66
Low Estimate 1.73 1.87 8.29 8.25
Coefficient of Variance 5.18 5.67 1.75 5.21

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 20 19 17
OVERWEIGHT 4 4 4
HOLD 7 7 8
UNDERWEIGHT 1 2 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Gilead Sciences Inc. - GILD

Date Name Shares Transaction Value
Jan 7, 2026 Dietmar P. Berger Chief Medical Officer 16,326 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 7, 2026 Dietmar P. Berger Chief Medical Officer 9,382 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $121.6 per share 1,140,851.20
Jan 7, 2026 Dietmar P. Berger Chief Medical Officer 41,179 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 20, 2025 Andrew D. Dickinson Chief Financial Officer 154,555 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $125.23 per share 19,354,922.65
Nov 20, 2025 Johanna Mercier Chief Commercial Officer 135,193 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $66.64 per share 9,009,261.52
Nov 20, 2025 Johanna Mercier Chief Commercial Officer 109,669 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $125.83 per share 13,799,650.27
Nov 20, 2025 Johanna Mercier Chief Commercial Officer 107,193 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $126.26 per share 13,534,188.18
Nov 20, 2025 Johanna Mercier Chief Commercial Officer 73,110 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 29, 2025 Deborah H. Telman EVP, Corporate Affairs & GC 38,315 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 29, 2025 Deborah H. Telman EVP, Corporate Affairs & GC 46,544 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 29, 2025 Deborah H. Telman EVP, Corporate Affairs & GC 42,721 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $116.2 per share 4,964,180.20
Jul 29, 2025 Deborah H. Telman EVP, Corporate Affairs & GC 29,875 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 29, 2025 Deborah H. Telman EVP, Corporate Affairs & GC 21,646 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 16, 2025 Jeffrey A. Bluestone Director 13,920 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $67.45 per share 938,904.00
Jul 16, 2025 Jeffrey A. Bluestone Director 8,920 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $109.74 per share 978,880.80
Jul 16, 2025 Jeffrey A. Bluestone Director 9,665 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Gilead Sciences Inc. in the News

Inside the race for a COVID-19 treatment pill

Pfizer and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG are racing to produce the first antiviral pill that people could take at early signs of the illness. Their shared goal: filling a key treatment hole by helping people recently-infected with coronavirus to avoid becoming seriously ill and needing hospitalization.

COVID-19 vaccine start-up files for IPO

The biotech startup behind the COVID-fox19 vaccine jointly developed by AstraZeneca PLC and the University of Oxford filed Friday with U.S. regulators for a public share offering. Vaccitech PLC said in a securities filing it plans to use the technology underpinning the vaccine to develop treatments targeting prostate cancer, hepatitis B and human papillomavirus.